Phase II Study Evaluating the Safety and Effectiveness of HRS-1780 Tablets Compared to Placebo in Adults With Primary Aldosteronism

What this Trial Is About

Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the efficacy and safety of HRS-1780 in adults diagnosed with primary aldosteronism. The study aims to compare HRS-1780 against a placebo in 60 participants to better understand its effects on blood pressure and related health measures. Participants will be randomly assigned to receive either HRS-1780 tablets or a placebo. The treatment period lasts up to 8 weeks, during which changes in systolic and diastolic blood pressure, both in the office and via 24-hour ambulatory monitoring, will be assessed. The study also monitors serum potassium and sodium levels, potassium supplementation needs, and kidney function during this time. During the trial, participants will undergo regular blood pressure measurements, laboratory tests for electrolytes and kidney function at weeks 2, 4, and 8, and monitoring of any adverse effects. The primary measure is the change from baseline in office systolic blood pressure by week 8. Safety and efficacy will be closely followed throughout the study, which is scheduled to complete by November 2026.

A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism